問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Obstetrics & Gynecology

Division of Endocrinology

Division of Pediatrics

更新時間：2023-09-19

牛道明Niu, Dau-Ming
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 10 個月

Recruiting Trial

8Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

牛道明

List

25Cases

2018-07-01 - 2022-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

常敏之
Taipei Veterans General Hospital

Division of Cardiovascular Diseases

2018-06-01 - 2020-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

常敏之
Taipei Veterans General Hospital

Division of Cardiovascular Diseases

2008-07-29 - 2010-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2007-06-01 - 2009-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2021-02-01 - 2024-01-31

Phase I/II

A Phase 1/2 Open-Label, Dose Escalation Study to Determine the Safety and Efficacy of BMN 307, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Phenylalanine Hydroxylase in Subjects With Phenylketonuria

  • Condition/Disease

    Phenylketonuria (PKU)

  • Test Drug

    BMN 307

Participate Sites
2Sites

Not yet recruiting2Sites

2017-12-08 - 2023-02-01

Phase III

A 26 Week, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase 3 Trial With a 26 Week Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 5 and 10 mg, and Saxagliptin 2.5 and 5 mg in Pediatric Patients With Type 2 Diabetes Mellitus Who Are Between 10 and Below 18 Years of Age

  • Condition/Disease

    Type 2 Diabetes Mellitus in Pediatric Patients

  • Test Drug

    Dapagliflozin / Saxagliptin

Participate Sites
3Sites

Recruiting2Sites

Suspended1Sites

牛道明
Taipei Veterans General Hospital

2013-06-01 - 2015-08-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2015-01-01 - 2015-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2016-03-24 - 2019-12-28

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2018-07-01 - 2021-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB